Loading...
•
Mar 31, 2022
Evolent Health Q1 2022 Earnings Report
Evolent Health reported strong organic growth and margin expansion, announcing two operating partner additions and one client expansion.
Key Takeaways
Evolent Health's Q1 2022 revenue reached $297.1 million, a 38.1% increase year-over-year. The company reported a net loss of $5.4 million, but achieved an adjusted EBITDA of $24.3 million. They also added two operating partnerships and announced a client expansion for 2023.
GAAP revenue increased by 38.1% to $297.1 million compared to Q1 2021.
Net loss attributable to common shareholders was $5.4 million, resulting in a net loss margin of (1.8)%.
Adjusted EBITDA reached $24.3 million, with an adjusted EBITDA margin of 8.2%.
Total Lives on Platform reached 20.3 million, including 2.1 million Evolent Health Services Lives and 18.2 million Clinical Solutions Lives.
Forward Guidance
For Q2 2022, Evolent anticipates revenue between $290.0 million and $305.0 million, and adjusted EBITDA between $18.0 million and $23.0 million. For the full year 2022, revenue is expected to be between $1.16 billion and $1.21 billion, and adjusted EBITDA between $85.0 million and $95.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...